The Genome of Progress: How Shanghai is Programming the Future of Biotech Across the Yangtze Delta

Section 1: The Silicon Valley of Biotech• 2025 Industry Snapshot:- Shanghai now hosts 38% of China's Class III medical device approvals- Zhangjiang Biotech Base attracts $9.2B in annual R&D investment- Regional talent pool exceeds 210,000 special